+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Biosimilars Market 2023-2027

  • PDF Icon

    Report

  • 120 Pages
  • November 2022
  • Region: Global
  • TechNavio
  • ID: 5395376
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The biosimilars market is poised to grow by $42227.12 mn during 2023-2027, accelerating at a CAGR of 23% during the forecast period. The report on the biosimilars market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by price advantage of biosimilars over biologics, the patent expiry of major biologics, and government initiatives to increase the use of biosimilar medicines.

The biosimilars market is segmented as below:

By Product Type

  • Monoclonal antibodies
  • Insulin
  • Human growth hormone
  • Others

By Application

  • Oncology and hematology
  • Endocrinology
  • Immunology
  • Nephrology

By Geographical Landscape

  • Europe
  • North America
  • Asia
  • Rest of World (ROW)
This study identifies the patients' and physicians' willingness to switch to biosimilars as one of the prime reasons driving the biosimilars market growth during the next few years. Also, therapeutic interchangeability regulations for biosimilars across countries and biosimilar's patent dance will lead to sizable demand in the market.

The report on the biosimilars market covers the following areas:

  • Biosimilars market sizing
  • Biosimilars market forecast
  • Biosimilars market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biosimilars market vendors that include AbbVie Inc., Amgen Inc., Biocon Ltd., Biogen Inc., Boehringer Ingelheim International GmbH, Celltrion Healthcare Co. Ltd., Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Gedeon Richter Plc, Halozyme Therapeutics Inc, Intas Pharmaceuticals Ltd., Mabion S.A., Novartis AG, Pfizer Inc., Samsung Biologics Co. Ltd., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the biosimilars market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Application
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Global biosimilars market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on Global biosimilars market 2017 - 2021 ($ million)
4.2 Product Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
4.3 Application Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Application Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Product Type
6.1 Market segments
Exhibit 30: Chart on Product Type - Market share 2022-2027 (%)
Exhibit 31: Data Table on Product Type - Market share 2022-2027 (%)
6.2 Comparison by Product Type
Exhibit 32: Chart on Comparison by Product Type
Exhibit 33: Data Table on Comparison by Product Type
6.3 Monoclonal antibodies - Market size and forecast 2022-2027
Exhibit 34: Chart on Monoclonal antibodies - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Monoclonal antibodies - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)
6.4 Insulin - Market size and forecast 2022-2027
Exhibit 38: Chart on Insulin - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Insulin - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Insulin - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Insulin - Year-over-year growth 2022-2027 (%)
6.5 Human growth hormone - Market size and forecast 2022-2027
Exhibit 42: Chart on Human growth hormone - Market size and forecast 2022-2027 ($ million)
Exhibit 43: Data Table on Human growth hormone - Market size and forecast 2022-2027 ($ million)
Exhibit 44: Chart on Human growth hormone - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on Human growth hormone - Year-over-year growth 2022-2027 (%)
6.6 Others - Market size and forecast 2022-2027
Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
6.7 Market opportunity by Product Type
Exhibit 50: Market opportunity by Product Type ($ million)
7 Market Segmentation by Application
7.1 Market segments
Exhibit 51: Chart on Application - Market share 2022-2027 (%)
Exhibit 52: Data Table on Application - Market share 2022-2027 (%)
7.2 Comparison by Application
Exhibit 53: Chart on Comparison by Application
Exhibit 54: Data Table on Comparison by Application
7.3 Oncology and hematology - Market size and forecast 2022-2027
Exhibit 55: Chart on Oncology and hematology - Market size and forecast 2022-2027 ($ million)
Exhibit 56: Data Table on Oncology and hematology - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Chart on Oncology and hematology - Year-over-year growth 2022-2027 (%)
Exhibit 58: Data Table on Oncology and hematology - Year-over-year growth 2022-2027 (%)
7.4 Endocrinology - Market size and forecast 2022-2027
Exhibit 59: Chart on Endocrinology - Market size and forecast 2022-2027 ($ million)
Exhibit 60: Data Table on Endocrinology - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Chart on Endocrinology - Year-over-year growth 2022-2027 (%)
Exhibit 62: Data Table on Endocrinology - Year-over-year growth 2022-2027 (%)
7.5 Immunology - Market size and forecast 2022-2027
Exhibit 63: Chart on Immunology - Market size and forecast 2022-2027 ($ million)
Exhibit 64: Data Table on Immunology - Market size and forecast 2022-2027 ($ million)
Exhibit 65: Chart on Immunology - Year-over-year growth 2022-2027 (%)
Exhibit 66: Data Table on Immunology - Year-over-year growth 2022-2027 (%)
7.6 Nephrology - Market size and forecast 2022-2027
Exhibit 67: Chart on Nephrology - Market size and forecast 2022-2027 ($ million)
Exhibit 68: Data Table on Nephrology - Market size and forecast 2022-2027 ($ million)
Exhibit 69: Chart on Nephrology - Year-over-year growth 2022-2027 (%)
Exhibit 70: Data Table on Nephrology - Year-over-year growth 2022-2027 (%)
7.7 Market opportunity by Application
Exhibit 71: Market opportunity by Application ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 73: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 74: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 75: Chart on Geographic comparison
Exhibit 76: Data Table on Geographic comparison
9.3 Europe - Market size and forecast 2022-2027
Exhibit 77: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 78: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 79: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 80: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.4 North America - Market size and forecast 2022-2027
Exhibit 81: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 82: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 83: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 84: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 85: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 86: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 87: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 88: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 Germany - Market size and forecast 2022-2027
Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.8 US - Market size and forecast 2022-2027
Exhibit 97: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 98: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 99: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 100: Data Table on US - Year-over-year growth 2022-2027 (%)
9.9 UK - Market size and forecast 2022-2027
Exhibit 101: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 102: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 103: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 104: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.10 China - Market size and forecast 2022-2027
Exhibit 105: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 106: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 107: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 108: Data Table on China - Year-over-year growth 2022-2027 (%)
9.11 Republic of Korea - Market size and forecast 2022-2027
Exhibit 109: Chart on Republic of Korea - Market size and forecast 2022-2027 ($ million)
Exhibit 110: Data Table on Republic of Korea - Market size and forecast 2022-2027 ($ million)
Exhibit 111: Chart on Republic of Korea - Year-over-year growth 2022-2027 (%)
Exhibit 112: Data Table on Republic of Korea - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 113: Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 114: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 115: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 116: Overview on factors of disruption
11.4 Industry risks
Exhibit 117: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 118: Vendors covered
12.2 Market positioning of vendors
Exhibit 119: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 120: AbbVie Inc. - Overview
Exhibit 121: AbbVie Inc. - Product / Service
Exhibit 122: AbbVie Inc. - Key offerings
12.4 Amgen Inc.
Exhibit 123: Amgen Inc. - Overview
Exhibit 124: Amgen Inc. - Product / Service
Exhibit 125: Amgen Inc. - Key offerings
12.5 Biocon Ltd.
Exhibit 126: Biocon Ltd. - Overview
Exhibit 127: Biocon Ltd. - Business segments
Exhibit 128: Biocon Ltd. - Key offerings
Exhibit 129: Biocon Ltd. - Segment focus
12.6 Biogen Inc.
Exhibit 130: Biogen Inc. - Overview
Exhibit 131: Biogen Inc. - Product / Service
Exhibit 132: Biogen Inc. - Key offerings
12.7 Boehringer Ingelheim International GmbH
Exhibit 133: Boehringer Ingelheim International GmbH - Overview
Exhibit 134: Boehringer Ingelheim International GmbH - Business segments
Exhibit 135: Boehringer Ingelheim International GmbH - Key news
Exhibit 136: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 137: Boehringer Ingelheim International GmbH - Segment focus
12.8 Celltrion Healthcare Co. Ltd.
Exhibit 138: Celltrion Healthcare Co. Ltd. - Overview
Exhibit 139: Celltrion Healthcare Co. Ltd. - Product / Service
Exhibit 140: Celltrion Healthcare Co. Ltd. - Key offerings
12.9 Dr Reddys Laboratories Ltd.
Exhibit 141: Dr Reddys Laboratories Ltd. - Overview
Exhibit 142: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 143: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 144: Dr Reddys Laboratories Ltd. - Segment focus
12.10 F. Hoffmann La Roche Ltd.
Exhibit 145: F. Hoffmann La Roche Ltd. - Overview
Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 147: F. Hoffmann La Roche Ltd. - Key news
Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus
12.11 Fresenius SE and Co. KGaA
Exhibit 150: Fresenius SE and Co. KGaA - Overview
Exhibit 151: Fresenius SE and Co. KGaA - Business segments
Exhibit 152: Fresenius SE and Co. KGaA - Key news
Exhibit 153: Fresenius SE and Co. KGaA - Key offerings
Exhibit 154: Fresenius SE and Co. KGaA - Segment focus
12.12 Gedeon Richter Plc
Exhibit 155: Gedeon Richter Plc - Overview
Exhibit 156: Gedeon Richter Plc - Business segments
Exhibit 157: Gedeon Richter Plc - Key news
Exhibit 158: Gedeon Richter Plc - Key offerings
Exhibit 159: Gedeon Richter Plc - Segment focus
12.13 Halozyme Therapeutics Inc
Exhibit 160: Halozyme Therapeutics Inc - Overview
Exhibit 161: Halozyme Therapeutics Inc - Product / Service
Exhibit 162: Halozyme Therapeutics Inc - Key offerings
12.14 Intas Pharmaceuticals Ltd.
Exhibit 163: Intas Pharmaceuticals Ltd. - Overview
Exhibit 164: Intas Pharmaceuticals Ltd. - Product / Service
Exhibit 165: Intas Pharmaceuticals Ltd. - Key offerings
12.15 Mabion S.A.
Exhibit 166: Mabion S.A. - Overview
Exhibit 167: Mabion S.A. - Product / Service
Exhibit 168: Mabion S.A. - Key offerings
12.16 Novartis AG
Exhibit 169: Novartis AG - Overview
Exhibit 170: Novartis AG - Business segments
Exhibit 171: Novartis AG - Key offerings
Exhibit 172: Novartis AG - Segment focus
12.17 Viatris Inc.
Exhibit 173: Viatris Inc. - Overview
Exhibit 174: Viatris Inc. - Business segments
Exhibit 175: Viatris Inc. - Key offerings
Exhibit 176: Viatris Inc. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 177: Inclusions checklist
Exhibit 178: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 179: Currency conversion rates for US$
13.4 Research methodology
Exhibit 180: Research methodology
Exhibit 181: Validation techniques employed for market sizing
Exhibit 182: Information sources
13.5 List of abbreviations
Exhibit 183: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Product Type
Exhibits 6: Executive Summary - Chart on Market Segmentation by Application
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 18: Historic Market Size - Data Table on Global biosimilars market 2017 - 2021 ($ million)
Exhibits 19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
Exhibits 20: Historic Market Size - Application Segment 2017 - 2021 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2022 and 2027
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits 26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits 27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits 28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits 29: Chart on Market condition - Five forces 2022 and 2027
Exhibits 30: Chart on Product Type - Market share 2022-2027 (%)
Exhibits 31: Data Table on Product Type - Market share 2022-2027 (%)
Exhibits 32: Chart on Comparison by Product Type
Exhibits 33: Data Table on Comparison by Product Type
Exhibits 34: Chart on Monoclonal antibodies - Market size and forecast 2022-2027 ($ million)
Exhibits 35: Data Table on Monoclonal antibodies - Market size and forecast 2022-2027 ($ million)
Exhibits 36: Chart on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)
Exhibits 37: Data Table on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)
Exhibits 38: Chart on Insulin - Market size and forecast 2022-2027 ($ million)
Exhibits 39: Data Table on Insulin - Market size and forecast 2022-2027 ($ million)
Exhibits 40: Chart on Insulin - Year-over-year growth 2022-2027 (%)
Exhibits 41: Data Table on Insulin - Year-over-year growth 2022-2027 (%)
Exhibits 42: Chart on Human growth hormone - Market size and forecast 2022-2027 ($ million)
Exhibits 43: Data Table on Human growth hormone - Market size and forecast 2022-2027 ($ million)
Exhibits 44: Chart on Human growth hormone - Year-over-year growth 2022-2027 (%)
Exhibits 45: Data Table on Human growth hormone - Year-over-year growth 2022-2027 (%)
Exhibits 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibits 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibits 48: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibits 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
Exhibits 50: Market opportunity by Product Type ($ million)
Exhibits 51: Chart on Application - Market share 2022-2027 (%)
Exhibits 52: Data Table on Application - Market share 2022-2027 (%)
Exhibits 53: Chart on Comparison by Application
Exhibits 54: Data Table on Comparison by Application
Exhibits 55: Chart on Oncology and hematology - Market size and forecast 2022-2027 ($ million)
Exhibits 56: Data Table on Oncology and hematology - Market size and forecast 2022-2027 ($ million)
Exhibits 57: Chart on Oncology and hematology - Year-over-year growth 2022-2027 (%)
Exhibits 58: Data Table on Oncology and hematology - Year-over-year growth 2022-2027 (%)
Exhibits 59: Chart on Endocrinology - Market size and forecast 2022-2027 ($ million)
Exhibits 60: Data Table on Endocrinology - Market size and forecast 2022-2027 ($ million)
Exhibits 61: Chart on Endocrinology - Year-over-year growth 2022-2027 (%)
Exhibits 62: Data Table on Endocrinology - Year-over-year growth 2022-2027 (%)
Exhibits 63: Chart on Immunology - Market size and forecast 2022-2027 ($ million)
Exhibits 64: Data Table on Immunology - Market size and forecast 2022-2027 ($ million)
Exhibits 65: Chart on Immunology - Year-over-year growth 2022-2027 (%)
Exhibits 66: Data Table on Immunology - Year-over-year growth 2022-2027 (%)
Exhibits 67: Chart on Nephrology - Market size and forecast 2022-2027 ($ million)
Exhibits 68: Data Table on Nephrology - Market size and forecast 2022-2027 ($ million)
Exhibits 69: Chart on Nephrology - Year-over-year growth 2022-2027 (%)
Exhibits 70: Data Table on Nephrology - Year-over-year growth 2022-2027 (%)
Exhibits 71: Market opportunity by Application ($ million)
Exhibits 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 73: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 74: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 75: Chart on Geographic comparison
Exhibits 76: Data Table on Geographic comparison
Exhibits 77: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits 78: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits 79: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 80: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 81: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibits 82: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibits 83: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits 84: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits 85: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits 86: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits 87: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 88: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits 90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits 91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibits 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)
Exhibits 97: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibits 98: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibits 99: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits 100: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits 101: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibits 102: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibits 103: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibits 104: Data Table on UK - Year-over-year growth 2022-2027 (%)
Exhibits 105: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibits 106: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibits 107: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibits 108: Data Table on China - Year-over-year growth 2022-2027 (%)
Exhibits 109: Chart on Republic of Korea - Market size and forecast 2022-2027 ($ million)
Exhibits 110: Data Table on Republic of Korea - Market size and forecast 2022-2027 ($ million)
Exhibits 111: Chart on Republic of Korea - Year-over-year growth 2022-2027 (%)
Exhibits 112: Data Table on Republic of Korea - Year-over-year growth 2022-2027 (%)
Exhibits 113: Market opportunity By Geographical Landscape ($ million)
Exhibits 114: Impact of drivers and challenges in 2022 and 2027
Exhibits 115: Overview on Criticality of inputs and Factors of differentiation
Exhibits 116: Overview on factors of disruption
Exhibits 117: Impact of key risks on business
Exhibits 118: Vendors covered
Exhibits 119: Matrix on vendor position and classification
Exhibits 120: AbbVie Inc. - Overview
Exhibits 121: AbbVie Inc. - Product / Service
Exhibits 122: AbbVie Inc. - Key offerings
Exhibits 123: Amgen Inc. - Overview
Exhibits 124: Amgen Inc. - Product / Service
Exhibits 125: Amgen Inc. - Key offerings
Exhibits 126: Biocon Ltd. - Overview
Exhibits 127: Biocon Ltd. - Business segments
Exhibits 128: Biocon Ltd. - Key offerings
Exhibits 129: Biocon Ltd. - Segment focus
Exhibits 130: Biogen Inc. - Overview
Exhibits 131: Biogen Inc. - Product / Service
Exhibits 132: Biogen Inc. - Key offerings
Exhibits 133: Boehringer Ingelheim International GmbH - Overview
Exhibits 134: Boehringer Ingelheim International GmbH - Business segments
Exhibits 135: Boehringer Ingelheim International GmbH - Key news
Exhibits 136: Boehringer Ingelheim International GmbH - Key offerings
Exhibits 137: Boehringer Ingelheim International GmbH - Segment focus
Exhibits 138: Celltrion Healthcare Co. Ltd. - Overview
Exhibits 139: Celltrion Healthcare Co. Ltd. - Product / Service
Exhibits 140: Celltrion Healthcare Co. Ltd. - Key offerings
Exhibits 141: Dr Reddys Laboratories Ltd. - Overview
Exhibits 142: Dr Reddys Laboratories Ltd. - Business segments
Exhibits 143: Dr Reddys Laboratories Ltd. - Key offerings
Exhibits 144: Dr Reddys Laboratories Ltd. - Segment focus
Exhibits 145: F. Hoffmann La Roche Ltd. - Overview
Exhibits 146: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 147: F. Hoffmann La Roche Ltd. - Key news
Exhibits 148: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 149: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 150: Fresenius SE and Co. KGaA - Overview
Exhibits 151: Fresenius SE and Co. KGaA - Business segments
Exhibits 152: Fresenius SE and Co. KGaA - Key news
Exhibits 153: Fresenius SE and Co. KGaA - Key offerings
Exhibits 154: Fresenius SE and Co. KGaA - Segment focus
Exhibits 155: Gedeon Richter Plc - Overview
Exhibits 156: Gedeon Richter Plc - Business segments
Exhibits 157: Gedeon Richter Plc - Key news
Exhibits 158: Gedeon Richter Plc - Key offerings
Exhibits 159: Gedeon Richter Plc - Segment focus
Exhibits 160: Halozyme Therapeutics Inc - Overview
Exhibits 161: Halozyme Therapeutics Inc - Product / Service
Exhibits 162: Halozyme Therapeutics Inc - Key offerings
Exhibits 163: Intas Pharmaceuticals Ltd. - Overview
Exhibits 164: Intas Pharmaceuticals Ltd. - Product / Service
Exhibits 165: Intas Pharmaceuticals Ltd. - Key offerings
Exhibits 166: Mabion S.A. - Overview
Exhibits 167: Mabion S.A. - Product / Service
Exhibits 168: Mabion S.A. - Key offerings
Exhibits 169: Novartis AG - Overview
Exhibits 170: Novartis AG - Business segments
Exhibits 171: Novartis AG - Key offerings
Exhibits 172: Novartis AG - Segment focus
Exhibits 173: Viatris Inc. - Overview
Exhibits 174: Viatris Inc. - Business segments
Exhibits 175: Viatris Inc. - Key offerings
Exhibits 176: Viatris Inc. - Segment focus
Exhibits 177: Inclusions checklist
Exhibits 178: Exclusions checklist
Exhibits 179: Currency conversion rates for US$
Exhibits 180: Research methodology
Exhibits 181: Validation techniques employed for market sizing
Exhibits 182: Information sources
Exhibits 183: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global biosimilars market: AbbVie Inc., Amgen Inc., Biocon Ltd., Biogen Inc., Boehringer Ingelheim International GmbH, Celltrion Healthcare Co. Ltd., Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Gedeon Richter Plc, Halozyme Therapeutics Inc, Intas Pharmaceuticals Ltd., Mabion S.A., Novartis AG, Pfizer Inc., Samsung Biologics Co. Ltd., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is patients' and physicians' willingness to switch to biosimilars.`

According to the report, one of the major drivers for this market is the price advantage of biosimilars over biologics.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Amgen Inc.
  • Biocon Ltd.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Celltrion Healthcare Co. Ltd.
  • Dr Reddys Laboratories Ltd.
  • F. Hoffmann La Roche Ltd.
  • Fresenius SE and Co. KGaA
  • Gedeon Richter Plc
  • Halozyme Therapeutics Inc
  • Intas Pharmaceuticals Ltd.
  • Mabion S.A.
  • Novartis AG
  • Pfizer Inc.
  • Samsung Biologics Co. Ltd.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.